Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma†
Alexandra Walsh MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Search for more papers by this authorDavid R. Kelly MD
Department of Pathology, University of Alabama at Birmingham, and Children's Hospital of Alabama, Birmingham, Alabama
Search for more papers by this authorYoginder N. Vaid MD
Department of Radiology, University of Alabama at Birmingham, and Children's Hospital of Alabama, Birmingham, Alabama
Search for more papers by this authorLee M. Hilliard MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Search for more papers by this authorCorresponding Author
Gregory K. Friedman MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Department of Pediatrics, 1600 7th Ave South, ACC 512, Birmingham, AL 35233-1711.===Search for more papers by this authorAlexandra Walsh MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Search for more papers by this authorDavid R. Kelly MD
Department of Pathology, University of Alabama at Birmingham, and Children's Hospital of Alabama, Birmingham, Alabama
Search for more papers by this authorYoginder N. Vaid MD
Department of Radiology, University of Alabama at Birmingham, and Children's Hospital of Alabama, Birmingham, Alabama
Search for more papers by this authorLee M. Hilliard MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Search for more papers by this authorCorresponding Author
Gregory K. Friedman MD
Division of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama
Department of Pediatrics, 1600 7th Ave South, ACC 512, Birmingham, AL 35233-1711.===Search for more papers by this authorConflict of interest: Nothing to report
Abstract
Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC. Pediatr Blood Cancer. 2010;55:1217–1220. © 2010 Wiley-Liss, Inc.
REFERENCES
- 1 van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, et al. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995; 121: 478–486.
- 2 Davis CJ, Jr. Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995; 19: 1–11.
- 3
Avery RA,
Harris JE,
Davis CJ, Jr., et al.
Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor.
Cancer
1996;
78:
128–132.
10.1002/(SICI)1097-0142(19960701)78:1<128::AID-CNCR18>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 4 Watanabe IC, Billis A, Guimaraes MS, et al. Renal medullary carcinoma: Report of seven cases from Brazil. Mod Pathol 2007; 20: 914–920.
- 5
Stahlschmidt J,
Cullinane C,
Roberts P, et al.
Renal medullary carcinoma: Prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement.
Med Pediatr Oncol
1999;
33:
551–557.
10.1002/(SICI)1096-911X(199912)33:6<551::AID-MPO5>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 6 Simpson L, He X, Pins M, et al. Renal medullary carcinoma and ABL gene amplification. J Urol 2005; 173: 1883–1888.
- 7 Yang XJ, Sugimura J, Tretiakova MS, et al. Gene expression profiling of renal medullary carcinoma: Potential clinical relevance. Cancer 2004; 100: 976–985.
- 8 Albadine R, Wang W, Brownlee NA, et al. Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol 2009; 82: 735–740.
- 9 Cheng, J.X., Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol 2008; 21: 647–652.
- 10 Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: The Bronx experience. Urology 2007; 70: 878–882.
- 11 Selby DM, Simon C, Foley JP, et al. Renal medullary carcinoma: Can early diagnosis lead to long-term survival? J Urol 2000; 163: 1238.
- 12 Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: Report of three cases and literature review. Urology 2008; 72: 659–663.
- 13 Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44: 407–411.
- 14 Bell MD. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediatr Blood Cancer 2006; 47: 228.
- 15 Ronnen BA, Kondagunta GV, Motzer RJ., Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24: e14.
